darapladib

Phase 3Small molecule

GSK

darapladib is one of 125 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

124

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Coronary AtherosclerosisActive, not recruiting

Myocardial InfarctionActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Type 2 Diabetes MellitusPhase 1

Active, not recruiting

Coronary AtherosclerosisPhase 3

Active, not recruiting

Myocardial InfarctionPhase 3

Active, not recruiting

Diabetic Macular EdemaPhase 2

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

darapladib

GSK

Phase 3

1 2

Byetta

AstraZeneca

Preclinical

20 3

Tanzeum

GSK

Preclinical

10 4

Insulin 320

Novo Nordisk

Preclinical

43 5

Adenocard

Astellas

Preclinical

1 6

Myrbetriq

Dostinex

Golytely

Lantus

6 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

APL2 trials

Darapladib China PK

Completed· GSK logo

GSK·Phase 1·NCT02000804·24 enrolled

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

Completed· GSK logo

GSK·Phase 1·NCT01154114·24 enrolled

Diabetic Macular Edema1 trial

A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema

Completed· GSK logo

GSK·Phase 2·NCT01506895·54 enrolled

Interaction1 trial

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT01873339·26 enrolled

Tics1 trial

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

Completed· GSK logo

GSK·Phase 1·NCT01852565·36 enrolled

Renal Impairment1 trial

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

Completed· GSK logo

GSK·Phase 1·NCT01711723·16 enrolled

9 more indications

Statin1 trial

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT01751074·18 enrolled

Myocardial Infarction1 trial

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Completed· GSK logo

GSK·Phase 3·NCT01000727·13,026 enrolled

Concentration1 trial

A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men

Completed· GSK logo

GSK·Phase 1·NCT00551317·18 enrolled

Cardiovascular Events1 trial

SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)

Completed· GSK logo

GSK··NCT01636271·28,855 enrolled

Type 2 Diabetes Mellitus1 trial

Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

Completed· GSK logo

GSK·Phase 1·NCT02058641·9 enrolled

Atherosclerotic Plaque1 trial

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Completed· GSK logo

GSK·Phase 3·NCT00799903·15,828 enrolled

Heart1 trial

Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

Completed· GSK logo

GSK·Phase 1·NCT00411073·72 enrolled

Coronary Atherosclerosis1 trial

Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans

Completed·MMayo Clinic·Phase 3·NCT01067339·70 enrolled

Unspecified1 trial

A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

Completed· GSK logo

GSK·Phase 1·NCT00743860·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for darapladib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — darapladib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for darapladib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

darapladib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

APL2 trials

Diabetic Macular Edema1 trial

Interaction1 trial

Tics1 trial

Renal Impairment1 trial

Statin1 trial

Myocardial Infarction1 trial

Concentration1 trial

Cardiovascular Events1 trial

Type 2 Diabetes Mellitus1 trial

Atherosclerotic Plaque1 trial

Heart1 trial

Coronary Atherosclerosis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News